ClinicalTrials.gg
CompletedNCT02181660Updated Nov 6, 2024

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 interventional study of Gilteritinib in Acute Myeloid Leukemia (AML), sponsored by Astellas Pharma Inc. Completed at 5 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Astellas Pharma Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
25th of 31
24 · median 97
Started
2014
the only one that year
Phase 1
6 of 31
1 open now
Registered
2nd of 31
by date
Lead sponsor
3 of 31
Astellas Pharma Inc

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 25th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 1, and was the 2nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The objectives of this study are to determine the safety and tolerability of ASP2215 as well as the maximum tolerated dose (MTD) based on the onset of dose limiting toxicity (DLT) and/or determine the recommended dose (RD) of ASP2215 for the next phase in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML).

Read the detailed description

This study will be conducted to determine the safety, tolerability, PK, PD, and efficacy of single and repeated oral dosing of ASP2215 once daily in patients with relapsed or refractory AML. After the determination of the MTD and/or RD, an expansion cohort might be set to further investigate the safety and efficacy of ASP2215.

This study will consist of a single-dose period (Cycle 0, 2 days) and a repeated-dose period (Cycle 1 and subsequent cycles, each cycle consisting of 28 days). The enrolled subjects will orally receive their assigned single dose in Cycle 0 (Day -2), followed by a 2-day observation period (dosing day inclusive). In Cycle 1 and subsequent cycles (one cycle is defined as 28 days), the subjects will receive oral ASP2215 once daily repeatedly until one of the discontinuation criteria is met. Another dosing regimen may be considered such as dosing twice daily based on the safety and PK data that will become available.

In this study, the Bayesian-Continual Reassessment Method (hereinafter, Bayesian-CRM) will be used as a reference for dose-escalation procedures, and based on the onset of DLTs, the RD level of the subsequent cohort will be set higher or lower. DLTs will be assessed during Cycle 0 and Cycle 1 (30 days).

ASP2215 may be escalated by one dose level if the subject meets the criteria at the end of each cycle after Cycle 1 and the investigator/sub-investigator judges escalation of ASP2215 is of clinical benefit. Dose reduction of ASP2215 will be considered if study drug-related toxicities are observed in a subject.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • AML
  • Acute myeloid leukemia
  • Gilteritinib
  • ASP2215
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is defined as morphologically documented primary or secondary acute myeloid leukemia (AML) according to the World Health Organization (WHO) criteria (2008) and fulfills one of the following:

    • to prior induction chemotherapy
    • Relapsed after achieving remission with prior therapy
  • Subject has an (ECOG) performance status of ≤ 2
  • Subject's interval from prior treatment to the time of study drug administration is at least 14 days for antineoplastic agents other than ASP2215 (except for hydroxyurea, which is given to control blast cells).
  • Subject's interval from prior treatment to the time of study drug (ASP2215) administration is at least 5 half-lives (if the half-life is unknown, 14 days) for other products or drugs used for therapy posthematopoietic stem cell transplantation ().

Exclusion criteria

Exclusion Criteria:

  • Subject was diagnosed with acute promyelocytic leukemia (APL).
  • Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis)
  • Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS)
  • Subject has persistent non-hematological toxicities of ≥ Grade 2 ( v4), with symptoms and objective findings, due to prior AML treatment (including chemotherapy, kinase inhibitors, immunotherapy, products, radiation therapy, and surgery)
  • Subject has received hematopoietic stem cell transplant () and falls under either of the following:

    • Is within 2 months of transplant
    • Has persistent and requiring treatment
    • Has persistent non-hematological toxicities of ≥ Grade 2 related to the transplant
  • Subject has clinically active central nervous system leukemia
  • Subject has disseminated intravascular coagulation (DIC)
  • Subject has had major surgery within 28 days prior to the first study drug administration
  • Subject has had radiation therapy within 28 days prior to the first study drug administration
  • Subject has congestive heart failure of class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram or Multiple Gate Acquisition () scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of \< 45%.
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of or of P-gp with such exceptions of antibiotics, antifungals, and antivirals that are considered absolutely essential for prevention or treatment of infections and for which the physician judged that there are no interchangeable drugs.
  • Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
  • Subject has an active uncontrollable infection
  • Subject is known to have (HIV) infection
  • Subject has active or C or other active hepatic disorders
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Dose Escalation Cohort

    ASP2215

    Drug: Gilteritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability assessed through adverse events to determine maximum tolerated dose

    Time frame: Up to 17 months

Secondary outcomes

  1. Response Rate

    Response Rate includes following parameters; CR rate, composite CR \[CR + CRp + CRi\] rate, overall response rate \[CRc + PR\], duration of response

    Time frame: Up to 16 months

  2. Pharmacokinetics of ASP2215 in plasma: AUCinf

    Area under the concentration-time curve from the time of dosing extrapolated to time infinity

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  3. Pharmacokinetics of ASP2215 in plasma: AUClast

    Area under the concentration-time curve from the time of dosing to the last measurable concentration

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  4. Pharmacokinetics of ASP2215 in plasma: AUC24

    Area under the plasma concentration time curve from time 0 to 24 hours

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  5. Pharmacokinetics of ASP2215 in plasma: AUC48

    Area under the plasma concentration time curve from time 0 to 48 hours

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  6. Pharmacokinetics of ASP2215 in plasma: Cmax

    Maximum concentration

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1 and Cycle 1 Day 28

  7. Pharmacokinetics of ASP2215 in plasma: C24

    Concentration at 24 hours

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1 and Cycle 1 Day 28

  8. Pharmacokinetics of ASP2215 in plasma: CLF

    Oral clearance

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1 and Cycle 1 Day 28

  9. Pharmacokinetics of ASP2215 in plasma: Lambda z

    Terminal first order elimination rate constant

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  10. Pharmacokinetics of ASP2215: tmax

    Time to attain Cmax

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1 and Cycle 1 Day 28

  11. Pharmacokinetics of ASP2215 in plasma: t1/2

    Apparent terminal elimination half-life

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  12. Pharmacokinetics of ASP2215 in plasma: Vz/F

    Apparent volume of distribution during the terminal elimination phase after oral dosing

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  13. Pharmacokinetics of ASP2215 in plasma: AUCtau

    Area under the plasma concentration time curve during a dosing interval

    Time frame: Cycle 1 Day 28

  14. Pharmacokinetics of ASP2215 in plasma: PTR

    Peak-trough ratio

    Time frame: Cycle 1 Day 28

  15. Pharmacokinetics of ASP2215 in plasma: Rac(AUC)

    Accumulation ratio calculated using the area under the concentration-time curve

    Time frame: Cycle 1 Day 28

  16. Pharmacokinetics of ASP2215 in plasma: Rac(Cmax)

    Accumulation ratio calculated using the maximum concentration

    Time frame: Cycle 1 Day 28

  17. Pharmacokinetics of ASP2215 in plasma: Rac derived t1/2

    t1/2 derived from accumulation index

    Time frame: Cycle 1 Day 28

  18. Pharmacokinetics of ASP2215 in plasma: Ctrough

    Plasma trough concentration

    Time frame: Cycle 1 Day 8, Day 15, Day 22, Day 28 and Day 29

  19. Pharmacokinetics of ASP2215 in urine: Ae24

    Amount of drug excreted in urine from time 0 to 24 hours

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  20. Pharmacokinetics of ASP2215 in urine: Ae48

    Amount of drug excreted in urine from time 0 to 48 hours

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  21. Pharmacokinetics of ASP2215 in urine: Ae24%

    Fraction of drug excreted into urine from time 0 to 24 hours as % of dose

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  22. Pharmacokinetics of ASP2215 in urine: Ae48%

    Fraction of drug excreted into urine from time 0 to 48 hours as % of dose

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1

  23. Pharmacokinetics of ASP2215 in urine: CLR

    Renal clearance

    Time frame: Cycle 0 Day -2 through Cycle 1 Day 1 and Cycle 1 Day 28

  24. Pharmacokinetics of ASP2215 in urine: Aetau

    Amount of drug excreted in urine during a dosing interval

    Time frame: Cycle 1 Day 28

  25. Pharmacokinetics of ASP2215 in urine: Aetau %

    Fraction of drug excreted in urine during a dosing interval

    Time frame: Cycle 1 Day 28

07

Study locations

5 sites
  • Site JP00002
    Aichi, Japan
  • Site JP00003
    Fukuoka, Japan
  • Site JP00001
    Gunma, Japan
  • Site JP00004
    Tokyo, Japan
  • Site JP00005
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jun 2016, 24 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 24 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 4, 2014
StartActual
Jun 16, 2014
Primary completionActual
Jun 27, 2016
CompletionActual
Jun 27, 2016
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02181660
Responsible party
Sponsor
First posted
Jul 4, 2014
Start date
Jun 16, 2014
Primary completion
Jun 27, 2016
Completion
Jun 27, 2016
Last update
Nov 6, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion